2020 American Transplant Congress
De Novo DSA in the Setting of Stable Renal Allograft Function Does Not Impair Long-Term Graft Survival
*Purpose: To determine the long-term outcome of renal allograft recipients with de novo DSA (dnDSA) in the setting of stable allograft function.*Methods: A single-center review…2020 American Transplant Congress
The Impact of Epitope Mismatch Load and Shared Targeting Epitopes between De Novo Donor Specific Antibody (DSA) and Non-DSA Third Party HLA Antibody on Lung Transplantation Outcomes
1Allogen Laboratories, Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH
*Purpose: Rapid advancements in HLA typing and antibody identification technologies allow for enhanced HLA compatibility assessment at the epitope level to aid in the reduction…2020 American Transplant Congress
Are HLA-DQ De Novo Donor-Specific Antibodies a Risk Factor for Acute Humoral Rejection?
*Purpose: To identify HLA-DQ de novo donor-specific antibodies (dnDSA) characteristics associated with acute humoral rejection (ABMR) and response to treatment.*Methods: We performed a retrospective analysis…2020 American Transplant Congress
Mid-Term Outcomes after Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?
*Purpose: De novo donor-specific HLA antibody (DSA) and antibody-mediated rejection (ABMR) are strongly associated with late allograft loss in renal transplant recipients. However, the impact…2020 American Transplant Congress
Clazakizumab (Anti-IL-6) Induces Foxp3+ Tregs in Highly HLA Sensitized Patients Desensitized for HLAi Transplantation (NCT03380962)
Cedars Sinai Medical Ctr, West Hollywood, CA
*Purpose: Interleukin-6 is an important inflammatory cytokine. In addition, it acts as a growth factor for B-cells, plasma cells and Th17 cells, inhibiting FoxP3+ Treg…2020 American Transplant Congress
Molecular Features of HLA Mismatches as Predictors of De Novo DSA Development: A Single Center Experience
*Purpose: Several molecular features (MoFs) of HLA mismatches (MMs) are currently used to predict the development of de novo donor-specific anti-HLA antibodies (dnDSA). The purpose…2020 American Transplant Congress
Preformed Anti-HLA Donor-Specific Antibodies Immunological Risk Assessment: The Importance of HLA Antibody Locus-Specificity
*Purpose: The screening of preformed donor-specific HLA antibodies (pfDSA) by single antigen bead assays has increased the complexity of pre-transplant patient risk stratification. We evaluated…2020 American Transplant Congress
The Art Rather Than the Science of Non-HLA Antibody Mediated Rejection in Heart Transplantation: A Single Center Experience
Cardiology, Baylor University Medical Center, Dallas, TX
*Purpose: The role of non-HLA antibodies (Ab) in HLA-DSA negative antibody mediated rejection (AMR) following heart transplant (HTx) remains largely unknown.*Methods: Retrospective analysis of all…2020 American Transplant Congress
Estimating Alloantibody Levels in Highly-Sensitized Renal Allograft Candidates Using Serial Dilutions
1Northwestern University, Chicago, IL, 2Mayo Clinic, Rochester, MN
*Purpose: Despite the new Kidney Allocation System and Kidney Paired Donation, renal allograft candidates with a >99.9% cPRA still have extremely low rates of transplantation…2020 American Transplant Congress
A Single Centre Report of Renal Transplantation Against a Positive Crossmatch Due to HLA-DP Donor Specific Antibodies without Prior Antibody Removal
*Purpose: In renal transplantation, the clinical effects of donor specific antibodies (DSA) against HLA-DP are unclear. We report successful kidney transplants in three highly sensitised…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 47
- Next Page »